Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renal clearance

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,038 result(s) found for: Renal clearance. Displaying page 1 of 102.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-003496-29 Sponsor Protocol Number: I13034 Start Date*: 2014-10-24
    Sponsor Name:University Hospital, Limoges
    Full Title: Designing a Bayesian model of the plasma clearance of Calcium edetate de sodium, with a limited sampling strategy for the calculation of Glomerular Filtration Rate (GFR) and validity assessment com...
    Medical condition: Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008246-20 Sponsor Protocol Number: ABR 25995 Start Date*: Information not available in EudraCT
    Sponsor Name:Radboud University Nijmegen Medical Center, Department of Anaesthesiology, Pain and Palliative Medic
    Full Title: Evaluation of the efficacy and safety of sugammadex (Bridion) in children with renal failure.
    Medical condition: Sugammadex is a selective relaxant binding agent, which is administered in case of a rocuronium-induced neuromuscular block, during general anaesthesia. The aim of the trial is to investigate the u...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038443 Renal failure and impairment HLT
    9.1 10009119 Chronic renal failure LLT
    9.1 10014647 End stage renal failure LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000856-16 Sponsor Protocol Number: DTG_HD Start Date*: 2015-05-27
    Sponsor Name:Fundació Lluita contra la SIDA
    Full Title: Removal of dolutegravir by hemodialysis in HIV-infected patients with end-stage renal disease.
    Medical condition: HIV-infected patients with end-stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10068341 HIV-1 infection LLT
    17.1 100000004857 10014646 End stage renal disease (ESRD) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-003081-32 Sponsor Protocol Number: 1160.166 Start Date*: 2012-04-18
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: An exploratory study to investigate the pharmacokinetics and effects of DABIgatran etexilate in patients with stable severe RENAL disease: DabiRenal
    Medical condition: Chronic kidney disease and coagulation
    Disease: Version SOC Term Classification Code Term Level
    15.0 10022891 - Investigations 10060318 Anticoagulation drug level PT
    15.0 10038359 - Renal and urinary disorders 10038444 Renal failure chronic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-004099-26 Sponsor Protocol Number: 6.version,september2011 Start Date*: 2009-12-10
    Sponsor Name:Departmnet of nephrology
    Full Title: Randomised trial on combined effects of dual blockade of the renin angiotensin system and phosphate binding in diabetic and non-diabetic patients with impaired renal function.
    Medical condition: decreased renal function (CKD II-IV), creatinin clearance 15-90 ml/min
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    18.0 10038359 - Renal and urinary disorders 10013231 Disorder kidney LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-000606-75 Sponsor Protocol Number: IP-001-06 Start Date*: 2007-03-27
    Sponsor Name:IPERBOREAL PHARMA
    Full Title: Assessment of dialytic efficacy and tolerability of a peritoneal dialysis solution for notturnal exchange containing L-Carnitine in End Stage Renal Disease Patients (ESRD) in Automatised Peritonea...
    Medical condition: Utilization of a peritoneal solution containing L-Carnitine as osmotic agent in the treatment of ESRD patients with APD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038444 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016159-23 Sponsor Protocol Number: ViRTUE-2009 Start Date*: 2011-10-18
    Sponsor Name:University Medical Center Groningen (UMCG)
    Full Title: Vitamin D in addition to RAAS blockade and dietary sodium for the Treatment of Urinary Excretion of albumin: the ViRTUE-study
    Medical condition: chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-019243-19 Sponsor Protocol Number: 004-09 Start Date*: 2012-06-18
    Sponsor Name:Angion Biomedica Corp.
    Full Title: Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation from Donors after Cardiac Death
    Medical condition: Patients suffering from end-stage renal disease, receiving a donor kidney from donors after cardiac death
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10014647 End stage renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-005298-23 Sponsor Protocol Number: IP-002-05 Start Date*: 2007-03-12
    Sponsor Name:IPERBOREAL PHARMA
    Full Title: Efficiency of L-Carnitine-containing Peritoneal Dialysis Solutions for diurnal exchanges in CAPD Patients with ESRD on Glucose and Lipid Metabolisms. Randomized, Parallel Study Compared versus a St...
    Medical condition: Patients affected by End stage renal disease ESRD treated with Continuous Ambulatory Peritoneal Dialysis CAPD .
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038444 Renal failure chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-001388-23 Sponsor Protocol Number: PRO-RENAL-REG-062 Start Date*: 2004-11-09
    Sponsor Name:Baxter R&D Europe SCRL
    Full Title: A Study to Evaluate the Efficacy and Safety of Extraneal Physiological pH Compared with Current Extraneal in Patients Receiving Continuous Ambulatory Peritoneal Dialysis (CAPD).
    Medical condition: End Stage Renal Disease patients receiving continuous ambulatiry peritoneal dialysis (CAPD)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10014646 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005300-13 Sponsor Protocol Number: IP-003-05 Start Date*: 2007-05-29
    Sponsor Name:IPERBOREAL PHARMA
    Full Title: Efficiency of L-Carnitine-containing Peritoneal Dialysis Solutions for diurnal exchanges in diabetes type 2 CAPD patients with ESRD on glucose metabolism. Randomized, parallel study compared versus...
    Medical condition: Patients affected by End Stage Renal Disease (ESRD) treated with Continuous Ambulatory Peritoneal Dialysis (CAPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038444 Renal failure chronic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000410-37 Sponsor Protocol Number: 310107 Start Date*: 2007-09-26
    Sponsor Name:University Of Tuebingen
    Full Title: Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-004152-10 Sponsor Protocol Number: EMPATHY Start Date*: 2020-01-30
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a sequential OFF-ON-OFF S...
    Medical condition: Obesity Renal chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000520-32 Sponsor Protocol Number: FG-506-02-42 Start Date*: 2005-01-26
    Sponsor Name:Fujisawa GmbH
    Full Title: A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION OF TACROLIMUS AND MYCOPHENOLATE MOFETIL BASED REGIMEN WITH OR WITHOUT INDUCTION IN ELDERLY RECIPIE...
    Medical condition: Patients with end stage kidney disease who will undergo primary renal transplantion or retransplantation
    Disease: Version SOC Term Classification Code Term Level
    7.0 10014646 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000457-34 Sponsor Protocol Number: FG-506-02-40 Start Date*: 2004-10-19
    Sponsor Name:Fujisawa GmbH
    Full Title: A MULTICENTRE, RANDOMISED, OPEN CLINICAL STUDY TO COMPARE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF TACROLIMUS WITH SIROLIMUS VERSUS TACROLIMUS WITH MYCOPHENOLATE MOFETIL IN KIDNEY TRANSP...
    Medical condition: Patients with end stage kidney disease who will undergo primary renal transplantation or retransplantation.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10014646 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-004990-13 Sponsor Protocol Number: KRM-307 Start Date*: 2007-10-17
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation [...]
    1. Mitsubishi Tanabe Pharma Corporation
    2. KUREHA CORPORATION
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease includin...
    Medical condition: Moderate to Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-004989-17 Sponsor Protocol Number: KRM-306 Start Date*: 2007-10-17
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation [...]
    1. Mitsubishi Tanabe Pharma Corporation
    2. KUREHA CORPORATION
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease
    Medical condition: Moderate to Severe Chronic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002721-99 Sponsor Protocol Number: CT114-2022-01 Start Date*: 2023-03-28
    Sponsor Name:Klinikum Nürnberg
    Full Title: Natriuretic-ureothelic adaptation of body fluid homeostasis during SGLT-2 inhibition and/or mineralocorticoid receptor modulation in patients with chronic kidney disease. A 4-arm, double-blind, dou...
    Medical condition: Stage 3 chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000773-23 Sponsor Protocol Number: I4M-MC-MRAC Start Date*: 2012-04-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Study of the Safety and Efficacy of LY2623091 in Chronic Kidney Disease Patients
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-003866-16 Sponsor Protocol Number: AP REN 01-01 Start Date*: 2009-03-03
    Sponsor Name:AM-Pharma B.V.
    Full Title: A Phase-II, double-blind, randomized, placebo-controlled proof of concept study on the safety and early efficacy of Alkaline Phosphatase in sepsis patients with Renal Failure.
    Medical condition: Sepsis with Renal Failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040050 Sepsis NOS LLT
    9.1 10038435 Renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:40:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA